Prospective study of 6 months of evolution in people with type 1 diabetes with insulin multidose (MDI) and HbA1c> 7%. Patients were evaluated clinical, metabolic and psychological baseline and at 6 months, with a telematic visit at 3 months. We analyzed: glycemic control (HbA1c), glycemic variability (SD and MAGE), depressive symptoms (BDI-II), anxiety (STAI), treatment-related (DDS) distress, fear of hypoglycemia (FH-15), adhesion treatment (SCI-R), quality of life (DQOL) and treatment satisfaction (DTSQ) and the platform.

Inclusion Criteria:

• Patients with DM1 plus 1 year of evolution.
• Age ≥18 and <65 years.
• HbA1c prior to study inclusion> 7%.
• MDI intensive insulin therapy in basal-bolus regimen.
• Patients candidates for telemonitoring. Approximately 50% of the patients should work with phone or tablet with Android operating system with active data rate to use wireless solution (bluetooth) OnLine MenaDiab® telemedicine. The remaining patients will work with the USB cable solution telemedicine MenaDiab® OnLine.
• Patients who have given written informed consent.

Exclusion Criteria:

• Treatment with ISCI.
• Chronic kidney disease, liver disease, thyroid dysfunction (hypothyroidism except properly treated and controlled).
• Pregnant or planning pregnancy.
• Diabetes mellitus type 2.
• Severe psychological disorders.
• Lack of cooperation (informed consent).
• Patients who are participating in other clinical studies.